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Introduction
Patients with Duchenne muscular dystrophy (DMD) generally succumb to respiratory failure by the third decade of life due to disease involvement of the diaphragm and other respiratory muscles. 1 Although pharmacologic treatment with corticosteroids may delay disease progression, 2 definitive therapy would require replacing the missing gene product, dystrophin. 3 Dystrophin is a large cytoskeletal protein that is normally present on the cytoplasmic aspect of the myofiber surface membrane. 3 Current evidence suggests that myofibers lacking dystrophin are abnormally susceptible to contraction-induced sarcolemmal damage, 4, 5 which secondarily leads to muscle fiber dysfunction, 6, 7 necrosis and eventual replacement of the lost fibers by adipose and connective tissue. Therefore, the muscle weakness found in DMD patients is due to both myofiber loss and impaired contractile function in the surviving myofiber population. 6 Gene therapy approaches in DMD should ideally be capable of reversing and/or preventing these changes without entailing significant adverse effects on muscle function.
Recombinant adenovirus vectors (AdV) are considered a promising means for delivering a functional dystrophin gene to muscle. Advantages of AdV as a vehicle for therapeutic gene transfer in DMD include the ability to infect nonreplicating muscle fibers, little apparent risk of oncogenesis and the availability of replication-defective variants at high viral titers. 8 However, a limitation to AdV-mediated gene transfer for the treatment of DMD is the transient nature of dystrophin expression in immunocompetent experimental animals, which is primarily due to a CD8 + cytotoxic T lymphocyte (CTL) response directed against the AdV-infected myofibers. 9, 10 In addition, we have recently reported that AdV-mediated transfer of reporter genes (as opposed to the therapeutic dystrophin gene) to diaphragm muscle caused significant impairment of force generation in normal as well as dystrophic (mdx) mice. 11 Further studies employing immunodeficient animal models 12 have pointed to at least two possible etiologies for this reduction in forcegenerating capacity: (1) a nonantigen-specific myofiber toxicity of early onset; and (2) an antigen-specific immune-based component of more delayed onset that is dependent upon intact CD8 + T cell activity. These findings raise the concern that toxic effects and immunologic responses to AdV administration could partially or even completely negate the therapeutic effects of dystrophin gene replacement.
In the present study, we show for the first time that AdV-mediated dystrophin minigene transfer can in fact alleviate the usual loss of muscle strength and histopathological changes found in dystrophin-deficient mdx muscles, provided that effective immunosuppression is also instituted in order to prevent CTL-mediated elimination of dystrophin-expressing myofibers. We also demonstrate that the appropriate AdV inoculum dosage lies within a fairly narrow therapeutic window, since the magnitude of both AdV toxicity and dystrophin expression are shown to increase in a dose-dependent manner. Finally, our data suggest that the degree of functional amelioration attainable in response to dystrophin gene replacement may vary with the level of underlying disease progression present at the time of AdV delivery, with initially more severely affected muscles potentially being less responsive to this form of therapy.
Results

Optimization of AdV-Dys inoculum dosage
We first attempted to identify the 'optimal' AdV-Dys inoculum dosage, which was defined as the AdV titer achieving the highest level of dystrophin expression while minimizing AdV-induced toxic effects on mdx muscle function. Accordingly, progressively increasing dosages of AdV-Dys particles were injected into separate diaphragms of mdx mice at 7-8 weeks of age, while using concomitant immunosuppression with the drug FK506 10 to eliminate potential confounding immunologic responses. Five days after AdV-Dys administration, analysis of the number of dystrophin-positive fibers in AdV-injected muscles revealed a direct correlation between AdV-Dys titer and successful myofiber transduction, as depicted in Figure 1 .
The effect of increasing AdV-Dys titer on maximal tetanic force production in adult mdx diaphragms is shown in Figure 2 . As compared with contralateral control hemidiaphragms that did not receive AdV-Dys, there was a slight trend toward reduced force production in AdVDys-injected diaphragms over the titer range of 1 × 10 10 to 1 × 10 11 particles per ml, but this did not reach statistical significance. However, at an AdV-Dys inoculum dosage of 5 × 10 11 particles per ml, there was a significant fall in maximal force-generating capacity as compared with control. Importantly, there was no apparent increase in muscle inflammation at the highest AdV titer despite the reduction in force-generating capacity. This is consistent with the early, direct toxic effect of high-titer AdV infection on myofiber function previously noted after AdVmediated transfer of reporter genes. 11, 12 Based on these results, we selected an AdV-Dys titer of 1 × 10 11 particles per ml as the optimal inoculum dosage representing the best compromise between high-level dystrophin gene transfer efficiency on the one hand, and minimization of cytotoxic effects on mdx myofibers with attendant adverse consequences for contractile function on the other.
Long-term dystrophin expression in adult mdx mice with immunosuppressive therapy Diaphragm and soleus muscles were injected with the optimal AdV-Dys titer and studied after 2 months of continuous immunosuppressive therapy. Under FK506 treatment, there was no evidence of AdV-induced inflammation and no significant loss of dystrophin-positive fibers in the diaphragm between 5 and 60 days after AdV injection (197 ± 63 and 183 ± 29, respectively; P = 0.82). The dystrophin-positive fibers were found to be present in a somewhat nonuniform pattern of distribution throughout both muscles, as can be seen in Figure 3 .
The total number of dystrophin-positive myofibers at 60 days after injection and their relative contribution to total muscle cross-sectional area in diaphragm as well as soleus are shown in Table 1 . The absolute number of dystrophin-positive fibers was significantly higher in dia- phragm than in the soleus muscle. However, due to the greater overall cross-sectional area of the excised diaphragm bundles, the mean contribution of dystrophinpositive fibers to total myofiber cross-sectional area actually tended to be higher in the soleus (P = 0.06).
Effect of AdV-Dys on dystrophic muscle histopathology Whereas myonuclei are normally found in a peripheral location in healthy muscle fibers, centrally located nuclei are characteristic of mouse myofibers that have undergone previous episodes of necrosis and subsequent regeneration. Therefore, quantification of the prevalence of central nucleation within mdx myofibers provides a useful index of the antecedent level of muscle necrosis. [13] [14] [15] Since AdV-Dys was administered to adult mdx animals that had already undergone cycles of necrosis, central nucleation was present within a substantial proportion of fibers at the time of gene transfer. In this regard, Figure  4 demonstrates that both centrally and peripherally nucleated myofibers were effectively transduced at 5 days after AdV-Dys delivery to adult mdx muscle.
The prevalence of central nucleation within dystrophin-positive and dystrophin-negative myofibers at 2 months after AdV injection is shown in Table 2 . In the AdV-Dys-injected hemidiaphragm, the prevalence of central nucleation was significantly lower in dystrophinpositive as compared with dystrophin-negative fibers, which strongly suggests that the incidence of necrosis had been substantially reduced in dystrophin-expressing fibers over the previous 2-month period. Moreover, there was no difference in the prevalence of central nucleation between dystrophin-negative fibers in AdV-Dys-injected hemidiaphragms and contralateral control hemidiaphragms that had not received AdV-Dys. Table 2 also indicates the effects of AdV-Dys administration on mdx limb muscle histopathology. In contrast to results obtained in the diaphragm, both dystrophinpositive and dystrophin-negative myofibers within AdVDys-injected soleus muscles demonstrated significantly less central nucleation than the contralateral control. Furthermore, there was no significant difference in the prevalence of central nucleation between dystrophinpositive and dystrophin-negative myofiber populations within the AdV-Dys-injected soleus muscles.
Ability of AdV-Dys to prevent further deterioration of contractile function in adult mdx muscles Data for mdx soleus and diaphragm twitch kinetics 2 months after AdV-Dys administration are provided in Table 3 . As can be seen, twitch contraction time and halfrelaxation time were both unaffected by AdV-Dys treatment in mdx soleus, as well as diaphragm muscles.
On the other hand, AdV-Dys administration had a substantial effect on the generation of maximal twitch force by mdx muscles, as shown in Figure 5 . Note that the baseline (control) force-generating capacity of the diaphragm was on average 27% lower than in soleus muscles obtained from the same animals, a finding that is consistent with the known accelerated progression of the dystrophic process in the mdx diaphragm. 16 Importantly, AdV-Dys administration was associated with a mean increase in maximal twitch force of approximately 33% in the mdx soleus muscle. In contrast, maximal twitch force production in the mdx diaphragm was not altered by AdV-Dys injection. Similar results were obtained for maximal tetanic force production as illustrated in Figure 6 , where baseline force production by the diaphragm was 49% lower than found in the soleus. Once again, a significant improvement in force-generating capacity was observed after AdV-Dys administration for the soleus muscle only, which amounted to an increase of approximately 14%. AdV-Dys efficacy in protecting adult mdx muscle from contraction-induced mechanical stress It was previously demonstrated that dystrophin-deficient myofibers exhibit an abnormally increased susceptibility to contraction-induced injury that is reflected by an accelerated loss of isometric force-generating capacity following the imposition of high-stress eccentric contractions. 5 Therefore, we also determined the effects of AdV-Dys administration on the vulnerability of mdx soleus muscles to this form of damage. As depicted in Figure 7 , both AdV-Dys and control mdx muscles exhibited reductions in force-generating capacity over the course of the eccentric contraction protocol. However, the absolute magnitude of maximal isometric force production remained significantly greater in AdV-Dys than in control soleus muscles throughout the imposition of highstress eccentric contractions. When expressed as a per- centage of its initial value rather than in absolute terms, force production at the end of the protocol did not differ significantly between the two groups, with the average final force being 77 and 79% of its initial value in the AdV-Dys and control muscles, respectively.
Discussion
The primary goal of gene therapy in DMD is to prevent the progressive deterioration of contractile function that leads to profound muscle weakness and eventual respiratory failure. In the present study, we employed recombinant adenoviruses to achieve expression of a truncated human dystrophin minigene in mdx mouse limb and diaphragm muscles. Although previous work in transgenic mdx mice indicates that the truncated dystrophin protein is somewhat less effective than its full-length counterpart, 14, 15 normal muscle strength can none the less be attained in mdx mice expressing the dystrophin minigene provided that the uniformity and level of expression are sufficiently high. 14 The fact that expression of even the truncated dystrophin is able to significantly ameliorate disease progression in transgenic mdx mice 14, 15 is encouraging for future attempts at gene therapy in DMD. However, it is important to recognize that the threshold level of dystrophin replacement needed to achieve a therapeutic effect may differ in the context of AdV-mediated gene transfer for a number of reasons. First, direct toxicity to myofibers may result from either exposure to AdV capsid proteins 17, 18 delivered in the initial inoculum or interference with normal cellular function by factors such as low-grade de novo expression of adenoviral genes.
19-21 Second, host immune responses directed against AdV-infected cells and attendant elimination of transduced myofibers can lead to adverse effects on force-generating capacity. 11, 12 Third, the use of germ cell correction of the genetic abnormality to prevent disease onset in transgenic animals differs substantially from the anticipated clinical scenario, which would involve treating individuals with established disease of varying degrees of severity.
The results of the present study provide insight into these issues. We have demonstrated that both gene transfer efficiency and myofiber toxicity are titer-dependent. Thus, at the highest AdV-Dys titer examined, a marked dissociation was observed between two commonly accepted endpoints of therapeutic efficacy, ie the number of dystrophin-expressing fibers and maximal force production. As suggested from transgenic mdx mice, complete prevention of muscle weakness is dependent upon reaching a certain absolute level of dystrophin gene expression distributed in a fairly uniform manner throughout the muscle. However, our data suggest that the AdV inoculum dosage required to achieve this level of dystrophin replacement in mature mdx animals may be very close to the threshold for acute AdV-induced myofiber toxicity. Therefore, the effective therapeutic index (ratio of desired therapeutic effects/undesirable toxic effects at a given dose) for AdV-Dys injection of mdx muscle appears to be relatively low.
The mechanisms underlying the acute dose-related toxicity observed after AdV administration appear to be of both immune and nonimmune origin. In immunocompetent mice receiving intratracheal instillation of AdV, McCoy et al 22 found that pulmonary inflammation occurred in a titer-dependent fashion irrespective of whether the viral genes were functionally intact or inactivated by ultraviolet (UV)-irradiation. Similar findings have been reported in the brain. 23 Such early inflammation is likely to be a response of the innate immune system to adenoviral capsid proteins per se, and would not require de novo expression of either adenoviral genes or the transgene in order to be stimulated. Although we were able to essentially eliminate this early inflammatory response by employing FK506 immunosuppressive therapy in the present study, adverse effects on myofiber function at high AdV titer were nonetheless observed. This may be explained, at least in part, by direct toxic effects of adenoviral proteins that are synthesized de novo after AdV infection of various target organs, including muscle.
19-21 Thus, while deletion of the E1 region should prevent major transactivation of adenoviral genes, socalled 'leaky' expression of adenoviral proteins can nevertheless occur, 19-21 possibly due to the presence of cellular E1-like factors. 24 This problem is probably most pronounced at a higher multiplicity of infection (MOI). In support of this idea, we have recently reported that when administered at high MOI, UV-irradiated AdV are less toxic to cultured myoblasts than transcriptionally active AdV particles. 12 Furthermore, UV-irradiated AdV also caused less force depression in vivo than transcriptionally active AdV administered to muscle at the equivalent particle dosage. 12 To date, AdV-mediated dystrophin gene transfer has generally been performed in immunologically immature (neonatal) mdx animals during the period that precedes the onset of major myofiber necrosis and reduced forcegenerating capacity. [25] [26] [27] Under these conditions, the immune response against AdV-infected cells is significantly less pronounced than in adult animals, and the longevity of dystrophin gene expression can thus be sufficient to reduce histological evidence of disease progression several weeks later 26 despite the absence of immunosuppressive therapy. However, in human patients suffering from DMD, the diagnosis is usually made at a much later stage due to the development of symptomatic muscle weakness. Therefore, both the immunological context and state of the underlying muscle disease differ substantially from the situation encountered in neonatal animals. Here we show for the first time that even in muscles of immunologically mature mdx animals that have undergone previous cycles of myofiber necrosis, AdV-mediated dystrophin minigene transfer is able to significantly ameliorate histopathological changes, provided that adequate immunosuppressive treatment is also given to allow the maintenance of dystrophin expression. To the extent that the prevalence of central nuclei within the mdx soleus muscle at 8 weeks of age (ie the age of vector administration in the present study) has been shown to be approximately 55%, 13 our finding of a similar prevalence of central nucleation in mdx soleus muscles 2 months after AdV-Dys injection suggests that further episodes of myofiber necrosis may have been minimal to absent following vector delivery. Additionally, an interesting observation was that dystrophin gene transfer to the soleus appeared to exert a protective effect (as determined by the prevalence of central nucleation) not only on those fibers demonstrating detectable dystrophin expression, but also on neighboring fibers that were dystrophin-negative in the same muscle section. This may be related at least in part to the fact that so-called dystrophin-negative fibers could have actually been dystrophin-positive in adjacent areas along the length of the myofiber, particularly if the nuclear domains covered by the AdV-Dys-containing myonuclei were relatively restricted. 28 These results are consistent with data obtained in certain mdx transgenic lines 14, 15 as well as female heterozygote mdx mice 28 in which the prevalence of muscle necrosis also appears to be quite low despite a mosaic pattern of dystrophin expression.
Importantly, this study also presents the first demonstration of increased isometric force-generating capacity after AdV-mediated dystrophin minigene transfer. Potential mechanisms underlying the improvement in force production include a reduction in the amount of fibrosis, as well as an inhibition of myofiber loss. With regard to the latter consideration in particular, AdV-mediated dystrophin minigene transfer has previously been demon-strated to be capable of preventing myofiber loss in mdx muscles. 9, 26 In the present study we have reported data obtained after only 8 weeks of dystrophin gene replacement in adult animals, but it is likely that differences between AdV-Dys-injected and nontreated muscles would become increasingly pronounced over time, assuming that the level of dystrophin expression were adequately maintained.
At 15 to 16 weeks of age, maximal isometric force production by the nontreated mdx diaphragm was already reduced to 40-50% of the normal value. 11, 12, 29 Therefore, the lack of improved muscle strength in the mdx diaphragm after AdV-Dys administration may be indicative of the response to AdV-mediated dystrophin gene replacement in muscles with a high level of pre-existent dystrophic pathology. If these findings are extrapolated to human DMD patients, this would imply that AdVmediated dystrophin gene transfer needs to be instituted very early in the course of the disease in order to achieve the desired therapeutic effect. Other intrinsic differences in the general characteristics of the two muscles (eg absolute workload, pattern of contraction, fiber-type composition, etc) could also conceivably contribute to differential responses to AdV-Dys administration. In addition, since the relative proportion of dystrophin-positive fibers tended to be lower in the diaphragm than in the soleus, this may also account for the reduced therapeutic efficacy observed in the former muscle. Finally, it should be pointed out that because the optimal titer was initially established for the diaphragm and then applied to both muscles, our data could actually underestimate the benefit achievable in the mdx soleus muscle after AdV-Dys administration if the optimal titers for the soleus and diaphragm were to differ.
In this study, the baseline improvement in force production observed in AdV-Dys-injected soleus muscles was maintained throughout a series of high-stress eccentric contractions, whereas the rate of decline was not significantly altered. These data are consistent with those recently reported by Decrouy et al, 30 who also found no significant alteration in the decline of force-generating capacity caused by eccentric contractions in adult mdx mouse diaphragms studied 3 weeks after plasmidmediated dystrophin minigene transfer. On the other hand, in neonatal mdx gastrocnemius muscles injected with AdV-Dys and studied 14 weeks later, 27 the percentage decline in force-generating capacity after eccentric contractions was significantly blunted. The results of these different studies further emphasize the potential variability in physiological responses to dystrophin gene transfer in relation to factors such as age, level of disease progression at the time of therapeutic gene delivery, and the duration as well as magnitude of successful dystrophin gene replacement.
Immunosuppressive agents such as corticosteroids 2 and cyclosporine 31 have been reported to have a transient beneficial effect on muscle strength in DMD in the absence of dystrophin gene replacement. Therefore, an important methodological aspect of this study was the use of contralateral muscles from the same mice as a control, which permitted determination of the independent effects of AdV-Dys injection. In addition, potential between-animal variations in the degree of immune modulation as well as disease progression were also controlled for in this fashion. The lack of either inflammation or significant loss of dystrophin-positive fibers at 2 months after AdV injection indicates that FK506 immunosuppressive therapy was effective in preventing CD8
+ CTL-mediated elimination of transduced myofibers, as we have previously reported. 10 It is therefore unlikely that antigen-specific adaptive immune responses against AdV-infected myofibers 9, 12 significantly interfered with the therapeutic efficacy of dystrophin gene transfer in this study. Whereas the dystrophin minigene replacement threshold for restoration of essentially normal muscle strength in transgenic mdx mice appears to lie at approximately 20% normal levels, 14 successful AdVmediated dystrophin replacement in approximately 17% of adult mdx myofibers produced less than complete correction of force-generating capacity. However, because neither vector toxicity nor pre-existent disease are present in the transgenic mouse model, the latter constitutes a best case scenario that does not accurately represent the anticipated situation for clinical use of AdV-mediated gene transfer in DMD patients. In addition, given that a fairly even distribution of dystrophin expression throughout the muscle cross-sectional area appears to be at least as important as the absolute dystrophin level in determining complete functional correction in transgenic animals, 14 it is likely that the limited diffusion of viral particles within AdV-injected muscles results in reduced therapeutic efficacy. Unfortunately, attaining higher dystrophin expression, both in terms of absolute quantity and uniformity of expression, would likely require the use of higher AdV dosages that lie within the myotoxic range. Therefore, although we have shown that mdx muscle function can be improved with the approach outlined here, a more complete prevention of dystrophic manifestations would appear to require further modification of both the vector and delivery modalities.
Our findings suggest a number of potential therapeutic strategies that have important implications for future application of AdV-mediated gene transfer to the treatment of DMD. It should be possible to reduce myofiber toxicity associated with adenoviral gene expression by creating further deletions of the viral genome within the vector. For example, the E4 region of the adenoviral genome encodes gene products with a number of functions including blockage of both host cell protein synthesis 32 and transcriptional activation of cellular growth proteins by the p53 tumor suppressor. 33 A potential role for E4 genes in target organ toxicity after AdV administration is suggested by a recent report that the early hepatotoxicity seen after E1-deleted AdV delivery to liver is reduced by using a doubly (E1 + E4)-deleted vector. 34 Furthermore, AdV that are deleted of all viral coding sequences have recently been developed, 35, 36 which have the additional advantage of being able to accommodate the more efficacious full-length dystrophin gene. The availability of vectors with a higher therapeutic index, in turn, could allow for higher AdV dosages to be employed, as well as repeated vector administration (under immunosuppression) into the same muscle. Alternatively, an effective method for vascular administration of AdV 9,37 could potentially permit a lower viral particle exposure per infected myofiber while at the same time allowing more widespread dissemination of AdV-Dys within the muscle, but this awaits further development.
In summary, AdV-mediated dystrophin minigene 377 transfer is capable of alleviating the usual progression of muscle weakness and histopathological changes in adult dystrophic animals with pre-existent muscle pathology. In order to achieve this beneficial effect, however, it is necessary: (1) to establish initially the optimal vector dosage representing the best compromise between maximal gene transfer efficiency and minimization of direct toxic effects; and (2) to provide effective immunosuppression to prevent T cell-mediated elimination of AdV-infected myofibers. Although further efforts to improve vector design and delivery methods are needed, these findings provide optimism for the eventual applicability of this treatment modality in DMD patients.
Materials and methods
Preparation of recombinant adenoviruses Adenoviral recombinants (AdV-Dys) containing the 6.3 kb dystrophin minigene 38 were constructed using E1/E3-deleted replication-defective serotype 5 human adenovirus as previously outlined in detail, 9 where the dystrophin cDNA was driven by human cytomegalovirus (CMV) promoter/enhancer elements inserted into the E1 region. The absence of E1-containing replicationcompetent AdV was confirmed using a sensitive PCR screening assay as previously described. 39 AdV-Dys titers (expressed as virus particles per ml) were determined in a spectrophotometer at 260 nm, and the ratio of total virus particles to infectious virus particles (100:1) was ascertained by plaque assay as previously described. 9 Animals and surgical procedures Dystrophin-deficient mdx mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). Mdx mice (50-60 days old) received injections of AdV-Dys (diluted in saline) into the hemidiaphragm and soleus hindlimb muscle on one side, whereas the same muscle on the contralateral side was injected with saline alone to serve as a within-animal control. The mdx diaphragm and soleus were selected in order to study the response to AdV-Dys in muscles with relatively severe and mild pre-existing functional impairment, respectively. 16 Briefly, the mice were anesthetized with ketamine (130 mg/kg) and xylazine (20 mg/kg) by intramuscular (i.m.) injection. A laparotomy was performed to reveal the abdominal surface of the diaphragm and the soleus was also surgically exposed to permit direct visualization of the muscle. Using the aid of a dissecting microscope, the diaphragm and soleus muscles were directly injected with AdV-Dys, as previously described in detail. 11 The injectate volume was roughly proportional to the muscle mass injected, amounting to 150 l and 15 l for hemidiaphragm and soleus, respectively. Animals recovered well from the surgery and demonstrated no untoward effects. The mice were killed at either 5 or 60 days after AdV-Dys administration.
In order to prevent immune-mediated elimination of AdV-infected myofibers and associated adverse effects on muscle function, 11, 12 all mice were injected with FK506 (5 mg/kg/day subcutaneously), a potent inhibitor of activated T-lymphocyte proliferation. 10 This immunosuppressive regimen was selected based upon our previous demonstration of sustained high-level dystrophin expression 2 months after AdV-Dys delivery to mdx mice. 10 Immunosuppression was begun on the day before AdV-Dys injection and continued until the animals were killed. The study was approved by the institutional animal ethics committee.
Measurement of isometric contractile properties
Mice were first anesthetized to achieve a loss of deep pain reflexes. Soleus muscles were then carefully removed in random order and tested to determine in vitro isometric contractile properties as described below in detail. After completing contractility measurements in the soleus muscles, mice were killed by anesthetic overdose and the diaphragm was removed en bloc with its intact rib cage as previously described. 5, 29 Contractility measurements were then made in random order on muscle strips obtained from each side of the diaphragm.
For both soleus and diaphragm, the freshly dissected muscles were briefly transferred to chilled Ringer's solution (composition: 119 mm NaCl, 4.7 mm KCl, 2.5 mm CaCl 2 , 1.2 mm KH 2 PO 4 , 1.2 mm MgSO 4 , 20 mm NaHCO 3 and 6 m d-tubocurarine chloride) perfused with 95% O 2 : 5% CO 2 (pH 7.4). The muscles were then mounted vertically in a jacketed tissue bath chamber filled with continuously perfused Ringer's solution maintained at 25°C, and a thermoequilibration period of 10 min was observed before initiating contractile measurements. One end of each muscle was securely anchored to a platform near the base of the chamber, while the opposite tendon was tied to the lever arm of a force transducer/length servomotor system (model 300B dual mode; Cambridge Technology, Watertown, MA, USA). 5, 29 The latter was mounted on a mobile micrometer stage (Newport Instruments, Toronto, Canada) to allow incremental adjustments of muscle length. Electrical field stimulation was induced via platinum plate electrodes placed into the bath on both sides of the muscle. Supramaximal stimuli with a monophasic pulse duration of 2 ms were delivered using a computer-controlled electrical stimulator (model S44; Grass Instruments, Quincy, MA, USA) connected in series to a power amplifier (model 6824A; Hewlett Packard, Palo Alto, CA, USA). Muscle force was displayed on a storage oscilloscope (Tektronix, Beaverton, OR, USA), and the data were simultaneously acquired to computer (Labdat/Anadat software; RHT-InfoData, Montreal, Canada) via an analog-to-digital converter at a sampling rate of 1000 Hz for later analysis.
After adjusting each muscle to optimal length (Lo, the length at which maximal twitch force is achieved), five twitch stimulations were recorded and the mean value was used to determine the following: twitch contraction time (time to peak force), twitch half-relaxation time (time for force to decrease to one-half of its peak value), and maximal isometric twitch force. Maximal isometric tetanic force was then measured by stimulating the muscle at 80 Hz for 1 s, allowing a clear plateau in force to be attained. The muscle was removed from the bath and Lo was directly measured under a dissecting microscope with microcalipers accurate to 0.1 mm. Total muscle strip cross-sectional area was determined by dividing muscle weight by its length and tissue density (1.06 g/cm 3 ). This allowed specific force (force/cross-sectional area) to be calculated, which was expressed as N/cm 2 .
Response to high-stress lengthening contractions Dystrophin is postulated to play an important role in helping to protect myofibers from potentially damaging stresses associated with muscle contraction. 4, 5 Therefore, after allowing a 10-min recovery period following the above measurements of isometric contractile properties, AdV-Dys-injected and control soleus muscles were also compared to determine their ability to withstand highstress eccentric (lengthening) contractions. The protocol has been described in detail previously. 5 Briefly, the soleus muscle was supramaximally stimulated at 80 Hz for 700 ms; the muscle was held at Lo during the initial 500 ms, whereas a step-change in length amounting to a 10% Lo increase was imposed by the computer-controlled servomotor lever arm during the final 200 ms of stimulation. A total of five such stimulations was performed, each being separated by a 2-min recovery period at Lo. The decline in maximal isometric force (obtained from the first 500 ms of muscle stimulation at Lo) during successive contractions was then recorded and used as an index of contraction-induced myofiber injury.
5,27
Dystrophin immunostaining and histopathology After completing the muscle function studies, the soleus and diaphragm were embedded in mounting medium and snap-frozen in isopentane pre-cooled with liquid N 2 . Transverse sections (6 m thick) were obtained in a cryostat and then fixed on slides in 1% acetone. Immunohistochemical procedures were carried out to detect dystrophin expression using a polyclonal antidystrophin (Cterminus) primary antibody and biotinylated secondary antibody with subsequent visualization by peroxidase staining, as previously outlined in detail. 9, 10 Muscle sections were also counterstained with hematoxylin and eosin (H & E) to allow determination of the prevalence of centrally nucleated myofibers, an indicator of the degree of previous necrosis and regeneration in mouse muscles. [13] [14] [15] Microscopically visualized sections were photographed using a video camera and the image was stored on a Macintosh computer. Analysis of the number and cross-sectional area of dystrophin-positive and dystrophin-negative myofibers on the entire muscle cross-section (averaging approximately 1500 and 700 myofibers for diaphragm and soleus, respectively) was performed using the public domain program NIH Image (version 1.49). The proportion of dystrophin-positive and dystrophin-negative myofibers exhibiting central nucleation was similarly determined.
Statistical analysis
To assess the response to different AdV-Dys titers, a oneway analysis of variance was employed along with posthoc application of Fisher's least significant difference test. Differences between AdV-Dys and contralateral control muscles were determined using Student's two-tailed t test for dependent samples. All values are means ± s.e. Statistical significance was defined as P Ͻ 0.05.
